Physician

Jeffrey A Parres, MD

According to 2025 Medicare claims, Jeffrey Parres, MD (NPI: 1619951027) practices urology in the St. Louis, MO-IL market, with the plurality of this provider's patient population coming from Madison, IL. This provider's primary affiliated billing organization is UROLOGY OF ST. LOUIS, INC. (NPI: 1528017191; TIN: 430835090) and primary practice location at 62062-8562. Parres is affiliated with the IRCCO (ACO ID: A2619), OSF Healthcare System (ACO ID: A3289), and SBL accountable care organization (ACO ID: A5147), participating under the MSSP model.

Parres' data goes back to 2015 and runs through 2024. For example, in 2024, this provider had 938 traditional Medicare patients, billed 8,364 HCPCS/CPT codes, and received $306,127 in Medicare payments. The top billing code was 99214 (Established patient office or other outpatient visit with moderate level of decision making, if using time, 30 minutes or more). Part D data shows 4,683 prescription claims across 939 beneficiaries totaling $1,896,637 in drug costs, led by Xtandi (Enzalutamide). DME data shows 63 claims. Open Payments data shows 47 records totaling $1,415. You can download detailed data with all billing codes (2015-2024). For more recent data, please contact us.

Over the past 10 years, this provider's Medicare Part B carrier billing has changed little. Concurrently, Part D prescription costs have risen steadily, from $203,206 to $1,896,637. For DME billing, this provider has fewer than 5 years of reported data, so a reliable trend cannot be assigned.

Part B Carrier Billing Trend

Medicare payment trend, with N of patients and claim lines in the table.

Year	Patients	Clm Lines	Payment
2015	1,030	74,054	$288,199
2016	1,140	11,572	$278,860
2017	930	5,839	$270,400
2018	923	5,606	$253,434
2019	820	7,537	$256,997
2020	853	6,327	$237,082
2021	885	4,975	$287,500
2022	819	4,555	$292,014
2023	945	6,954	$374,287
2024	938	8,364	$306,127

Part D Events Trend

Drug cost trend, with N of patients and prescription claims in the table.

Year	Patients	Claims	Drug Cost
2015	663	3,420	$203,206
2016	709	3,723	$193,789
2017	717	3,871	$278,617
2018	725	3,662	$300,245
2019	725	3,580	$207,878
2020	750	3,674	$605,655
2021	817	3,702	$1,054,497
2022	834	3,831	$857,076
2023	883	3,988	$1,585,876
2024	939	4,683	$1,896,637

DME Billing Trend

Medicare payment trend, with N of patients and DME claim records in the table.

Year	Patients	Claims	Payment
2015	N/R	82	$12,499
2016	N/R	81	$17,622
2017	N/R	46	$12,378
2018	N/R	29	$11,156
2019	N/R	25	$9,968
2020	N/R	34	$13,237
2021	N/R	35	$23,840
2022	N/R	17	$19,392
2023	N/R	23	$23,481
2024	N/R	63	$52,911

* / # = suppressed by CMS; 0 = reported zero; N/R = not reported or blank.

Top 5 Part B carrier billing codes in 2024

By total payments.

Code	Description	Patients	Clm Lines	Total Payment
99214	Established patient office or other outpatient visit with moderate level of decision making, if using time, 30 minutes or more	200	227	$85
99213	Established patient office or other outpatient visit with low level od decision making, if using time, 20 minutes or more	455	589	$57
G2211	Visit complexity inherent to evaluation and management associated with medical care services that serve as the continuing focal point for all needed health care services and/or with medical care services that are part of ongoing care related to a patient's	448	618	$11
36415	Insertion of needle into vein for collection of blood sample	139	165	$9
81003	Automated urinalysis test	387	505	$2

Top 5 Part D drugs in 2024

By total drug costs.

Drug	Generic	Claims	Total Day Supply	Total Drug Cost
Xtandi	Enzalutamide	91	2,730	$1,238,305
Nubeqa	Darolutamide	23	690	$318,449
Gemtesa	Vibegron	146	5,772	$94,649
Orgovyx	Relugolix	33	990	$89,323
Myrbetriq	Mirabegron	105	4,192	$62,909

Top 5 DME services in 2024

By Total Medicare Payment Amount.

HCPCS Code	HCPCS Description	Supplier Rental Indicator	Total Supplier Beneficiaries	Total Supplier Claims	Total Medicare Payment Amount
A4352	Intermittent urinary catheter; coude (curved) tip, with or without coating (teflon, silicone, silicone elastomeric, or hydrophilic, etc.), each	N	N/R	49	$46,127
A4351	Intermittent urinary catheter; straight tip, with or without coating (teflon, silicone, silicone elastomer, or hydrophilic, etc.), each	N	N/R	14	$6,783

Open Payments Summary in 2024

Category	Definition	Records	Total Reported Amount	Top Related Entity
General Payments	Reported payment or transfer-of-value amount.	47	$1,415	PROCEPT BioRobotics Corporation
Research Payments	Reported research-related payment or transfer-of-value amount.	0	$0	N/R
Ownership / Investment Interests	Reported value of ownership or investment interests.	0	$0	N/R

Explore More Providers

FAQ

What Medicare data is available for Jeffrey A. Parres, MD?

Tedicare shows public-source Medicare data for Jeffrey A. Parres, MD (NPI 1619951027), including provider identity, specialty, market context, Medicare Part B activity, Part D prescribing, DME records, Open Payments where available, billing organization details, and ACO affiliation signals where available. Profile data covers 2015-2024, with current attribution based on 2025 claims where available.

Does Jeffrey A. Parres, MD have ACO affiliation data?

Jeffrey A. Parres, MD is shown with ACO affiliation data for IRCCO (MSSP, ACO ID A2619), OSF Healthcare System (MSSP, ACO ID A3289), and SBL accountable care organization (MSSP, ACO ID A5147).

What billing organization is linked to Jeffrey A. Parres, MD?

Jeffrey A. Parres, MD is linked to UROLOGY OF ST. LOUIS, INC. (billing NPI 1528017191) in the available physician profile data.

Does Jeffrey A. Parres, MD have Open Payments data?

Jeffrey A. Parres, MD has 47 connected Open Payments records in the available 2024 summary data.

Can I download physician-level Medicare data from Tedicare?

Yes. Tedicare provides sample physician export data and paid custom physician data exports for research, planning, outreach, and market analysis. Exports can include physician profile fields, market and specialty context, billing organization details, ACO affiliation signals where available, and Medicare utilization data.